This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Artemether/Lumefantrine and Vivax Malaria

This study has been completed.
University of Kassala, Sudan
Information provided by (Responsible Party):
Ishag Adam, University of Khartoum Identifier:
First received: June 17, 2012
Last updated: January 16, 2013
Last verified: January 2013
The cure rate of artemether/lumefantrine in the treatment of vivax malaria.

Condition Intervention Phase
Vivax Malaria Drug: tablets artemether/lumefantrine Phase 3

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Artemether/Lumefantrine in the Treatment of Plasmodium Vivax Malaria in Eastern Sudan

Resource links provided by NLM:

Further study details as provided by Ishag Adam, University of Khartoum:

Primary Outcome Measures:
  • The cure rate [ Time Frame: 28 days ]
    The proportion of the cure patients

Secondary Outcome Measures:
  • Fever clearance time [ Time Frame: 28 days ]
    The time for fever clearance

  • Parasite clearance time [ Time Frame: 28 days ]
    The time for the parasite to clear

Enrollment: 38
Study Start Date: September 2011
Study Completion Date: September 2012
Primary Completion Date: September 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: artemether-lumefantrine
tablets (containing 20mg artemether and 120 mg lumefantrine) for three days
Drug: tablets artemether/lumefantrine
six doses of oral tablets of artemether/lumefantrine
Other Name: Quartem


Ages Eligible for Study:   5 Years to 80 Years   (Child, Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patients with vivax malaria

Exclusion Criteria:

  • severe malaria
  • pregnancy
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01625871

Kassala, Sudan, 249
Sponsors and Collaborators
University of Khartoum
University of Kassala, Sudan
  More Information

Additional Information:
Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Ishag Adam, Professor, University of Khartoum Identifier: NCT01625871     History of Changes
Other Study ID Numbers: vivax
Study First Received: June 17, 2012
Last Updated: January 16, 2013

Keywords provided by Ishag Adam, University of Khartoum:

Additional relevant MeSH terms:
Malaria, Vivax
Protozoan Infections
Parasitic Diseases
Artemether-lumefantrine combination
Antiprotozoal Agents
Antiparasitic Agents
Anti-Infective Agents
Antifungal Agents
Antiplatyhelmintic Agents
Anthelmintics processed this record on September 21, 2017